Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16376362 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2HPGDHTTEPHX2ALDH1A1 | |
| SCHEMBL17753479 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2HPGDHTTEPHX2ALDH1A1 | |
| SCHEMBL3460141 | 0.99 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDHTTEPHX2ALDH1A1 | |
| SCHEMBL3460109 | 0.99 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDHTTEPHX2ALDH1A1 | |
| SCHEMBL13029835 | 0.99 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDHTTEPHX2ALDH1A1 | |
| SCHEMBL3625357 | 0.99 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDHTTEPHX2ALDH1A1 | |
| SCHEMBL24136289 | 0.95 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTEPHX2ALDH1A1 | |
| SCHEMBL25962486 | 0.95 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTEPHX2ALDH1A1 | |
| SCHEMBL915308 | 0.95 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTEPHX2ALDH1A1 | |
| SCHEMBL14117834 | 0.91 | SMN1; SMN2 (0.43) | SMN1; SMN2HPGDHTTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | SMN1; SMN2 1281/4885HPGD 1106/4885HTT 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.